文献速递帕金森病与运动障碍

粪菌移植缓解帕金森病症状的安全性与疗效:随机安慰剂对照双盲研究

Safety and Efficacy of Fecal Microbiota Transplantation in Alleviating Symptoms of Parkinson's Disease: A Randomized, Placebo-Controlled, Double-Blinded Study.
PubMed 文献 · Ann Neurol · 2026-02-12

这项随机、安慰剂对照、双盲研究纳入59例帕金森病患者,按1:1随机接受Mbiotix粪菌或自体粪便安慰剂经结肠镜单次移植,观察12个月。结果显示两组MDS-UPDRS III「OFF」期评分无显著差异(1.50分,95%CI -4.28至7.28,p=1.00),但部分非运动症状在不同时间点有改善。单次粪菌移植不影响运动症状,可能通过肠脑轴改善非运动功能。

要点

  • 单次结肠镜粪菌移植未显著改善帕金森病运动症状(MDS-UPDRS III OFF期)。
  • 部分非运动症状在不同观察时间点出现改善,提示肠脑轴可能起作用。
  • 研究为随机双盲安慰剂对照设计,但样本量较小(59例),需进一步验证。

核心结论

  • 单次粪菌移植不影响帕金森病患者的运动症状表现,但可能通过肠脑轴改善非运动功能。

研究设计与样本

  • 随机、安慰剂对照、双盲研究,纳入59例帕金森病患者,按1:1随机分为Mbiotix粪菌组(28例,中位年龄65岁,15例男性)和自体粪便安慰剂组(31例,中位年龄63岁,14例男性),经结肠镜单次移植,观察12个月。

主要发现

  • 12个月时两组MDS-UPDRS III「OFF」期评分无显著差异(1.50分,95%CI -4.28至7.28,p=1.00)。
  • 部分非运动症状在不同研究时间点有改善。

临床怎么用

  • 单次粪菌移植暂不能作为改善帕金森病运动症状的常规手段,但非运动症状的潜在获益值得关注。

局限性

  • 样本量较小(59例),单次移植设计,非运动症状改善仅在不同时间点出现,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Changes in the gut microbiome may be involved in the pathogenesis and progression of Parkinson's disease (PD). This randomized, placebo-controlled, double-blinded study aimed to assess the effects of fecal microbiota transplantation (FMT) on the manifestation of the motor symptoms of PD (The Movement Disorders Society - Unified Parkinson's Disease Rating Scale Part III [MDS-UPDRS III]) over a 12 month long observation and non-motor symptoms as secondary objectives: the Movement Disorders Society-Non-Motor Rating Scale; EuroQol-5 Dimension; PD Quality-of-Life Questionnaire; Montreal Cognitive Assessment (MoCA); UPDRS I, II, and IV; Gastrointestinal Dysfunction Scale for PD; modified Constipation Assessment Scale; and levodopa equivalent dose. METHODS: The patients were randomly assigned to receive either fecal microbiota (Mbiotix, Human Biome Institute) or placebo (auto-fecal microbiota, prepared from the patient's stool) in a 1:1 ratio. The fecal microbiota transplantation was performed via colonoscopy. Assessments were performed before and after 12 months for the MoCA and at 1, 3, 6, and 12 months for the other scales. Intention-to-treat analysis was performed using a multivariable mixed regression model. RESULTS: Of the 59 patients included, 28 were randomly assigned to the Mbiotix group (median age = 65 years; 15 male patients) and 31 to the placebo group (median age = 63 years; 14 male patients). No significant differences were observed in the MDS-UPDRS III "OFF" state score at 12 months between groups (1.50 points, 95% confidence interval [CI] = -4.28 to 7.28, p = 1.00), however, some non-motor symptoms improved in different study timepoints. INTERPRETATION: A single FMT does not influence motor symptoms manifestation in patients with PD but could improve non-motor functioning via gut-brain axis. Trial registration information: Clinical Trial ID NCT05204641 was submitted on November 29, 2021. The first patient was enrolled on January 4, 2022. ANN NEUROL 2026;100:10-21.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Figura M, Milanowski Ł, Nowak JM, et al. Safety and Efficacy of Fecal Microbiota Transplantation in Alleviating Symptoms of Parkinson's Disease: A Randomized, Placebo-Controlled, Double-Blinded Study. Ann Neurol. 2026. PMID: 41674471. doi:10.1002/ana.78153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。